SCHEMBL4719310

SCHEMBL4719310

CC(C)CCCC(C)CCCC(C)CCCC(C)CCOC(=O)c1cccnc1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.61
LMNA P02545 6/20 0.59
ALDH1A1 P00352 4/20 0.50
MAPT P10636 4/20 0.50
KMT2A Q03164 3/20 0.50
MEN1 O00255 2/20 0.50
HPGD P15428 1/20 0.50
TDP1 Q9NUW8 3/20 0.49
GAA P10253 1/20 0.47
CYP1A2 P05177 1/20 0.47
CYP2C9 P11712 1/20 0.47
TSHR P16473 1/20 0.47
CYP2C19 P33261 1/20 0.47
KDM4E B2RXH2 1/20 0.46
MAPK1 P28482 1/20 0.45
USP2 O75604 1/20 0.45
NFKB1 P19838 2/20 0.44
NFKB2 Q00653 2/20 0.44
RELA Q04206 2/20 0.44
NPC1 O15118 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10489948 1.00 L3MBTL1 (0.61) L3MBTL1LMNAALDH1A1MAPTKMT2A
SCHEMBL14937203 0.89 L3MBTL1 (0.72) L3MBTL1LMNAALDH1A1MAPTKMT2A
SCHEMBL4411045 0.89 L3MBTL1 (0.67) L3MBTL1LMNAALDH1A1MAPTKMT2A
SCHEMBL29067692 0.87 LMNA (0.73) L3MBTL1LMNAALDH1A1MAPTKMT2A
SCHEMBL10458600 0.87 LMNA (0.73) L3MBTL1LMNAALDH1A1MAPTKMT2A
SCHEMBL10458609 0.87 LMNA (0.73) L3MBTL1LMNAALDH1A1MAPTKMT2A
SCHEMBL29242263 0.87 LMNA (0.73) L3MBTL1LMNAALDH1A1MAPTKMT2A
SCHEMBL14273831 0.84 TDP1 (0.57) LMNAALDH1A1KMT2ATDP1GAA
SCHEMBL3295954 0.84 TDP1 (0.57) LMNAALDH1A1KMT2ATDP1GAA
SCHEMBL28519762 0.84 TDP1 (0.57) LMNAALDH1A1KMT2ATDP1GAA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2004159-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS Biovitrum AB (publ) (SE) 2008-12-24 EP disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects BIOVITRUM AB (SE) 2008-02-28 US disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed
WO-2007104790-A1 AUTOIMMUNE CONDITIONS AND NADPH OXIDASE DEFECTS BIOVITRUM AB (PUBL) (SE) 2007-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080051451-A1 Autoimmune conditions and NADPH oxidase defects CYBB, NOX1, NOX5 L3MBTL1 3927/4885LMNA 4180/4885ALDH1A1 413/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.